<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>FDA Drug Listing Renewals Archives - Focal Point</title>
	<atom:link href="https://focalpointresearch.net/tag/fda-drug-listing-renewals/feed/" rel="self" type="application/rss+xml" />
	<link>https://focalpointresearch.net/tag/fda-drug-listing-renewals/</link>
	<description>Scientific, Regulatory and New Product Consultants</description>
	<lastBuildDate>Tue, 13 Oct 2026 14:19:14 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.5</generator>

<image>
	<url>https://focalpointresearch.net/wp-content/uploads/2021/11/cropped-focal_point_chart_03-32x32.jpg</url>
	<title>FDA Drug Listing Renewals Archives - Focal Point</title>
	<link>https://focalpointresearch.net/tag/fda-drug-listing-renewals/</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">126679100</site>	<item>
		<title>Reminder: US FDA Drug Listing Renewals 2026</title>
		<link>https://focalpointresearch.net/fda/reminder-us-fda-drug-listing-renewals-2026/</link>
		
		<dc:creator><![CDATA[Srishti Chaudhari]]></dc:creator>
		<pubDate>Tue, 13 Oct 2026 14:19:09 +0000</pubDate>
				<category><![CDATA[FDA]]></category>
		<category><![CDATA[Canadian Regulatory Consultants]]></category>
		<category><![CDATA[Consumer Products Regulatory Consultants]]></category>
		<category><![CDATA[Cosmetic Consultants]]></category>
		<category><![CDATA[FDA Drug Listing Renewals]]></category>
		<category><![CDATA[Focal Point Research]]></category>
		<category><![CDATA[FPR]]></category>
		<category><![CDATA[North American Regulatory Consultants]]></category>
		<category><![CDATA[North American Scientific Regulatory Affairs & Quality Assurance Consulting Firm]]></category>
		<category><![CDATA[Regulatory Affairs Consultants]]></category>
		<category><![CDATA[Regulatory Consultants]]></category>
		<category><![CDATA[Scientific Regulatory & New Product Consultants]]></category>
		<guid isPermaLink="false">https://focalpointresearch.net/?p=6016</guid>

					<description><![CDATA[<p>As the annual renewal period approaches, companies marketing drugs in the US should begin reviewing their FDA establishment registrations and drug listings. The annual renewal period runs from October 1 through December 31, 2026. During this period, companies should confirm that their establishment registration, product listings, NDC information, labeling, manufacturing sites, and other listing information [&#8230;]</p>
<p>The post <a href="https://focalpointresearch.net/fda/reminder-us-fda-drug-listing-renewals-2026/">Reminder: US FDA Drug Listing Renewals 2026</a> appeared first on <a href="https://focalpointresearch.net">Focal Point</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">As the annual renewal period approaches, companies marketing drugs in the US should begin reviewing their FDA establishment registrations and drug listings. The annual renewal period runs from October 1 through December 31, 2026. During this period, companies should confirm that their establishment registration, product listings, NDC information, labeling, manufacturing sites, and other listing information remain accurate. For drug listings that have not been updated during the calendar year, a blanket &#8220;no changes&#8221; certification may be submitted to keep the listings active for the following year.</p>



<p class="wp-block-paragraph">Companies should begin their portfolio review early to identify discontinued products, formulation or labeling changes, manufacturing-site updates and other changes that may require listing updates. Failure to complete the required annual certification or update during the renewal period can result in inactivation of drug listings, potentially affecting continued US distribution.</p>



<p class="wp-block-paragraph">Our team can help you manage all your FDA renewals. <a href="https://focalpointresearch.net/">Reach out to us</a> for more information.</p>
<p>The post <a href="https://focalpointresearch.net/fda/reminder-us-fda-drug-listing-renewals-2026/">Reminder: US FDA Drug Listing Renewals 2026</a> appeared first on <a href="https://focalpointresearch.net">Focal Point</a>.</p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">6016</post-id>	</item>
	</channel>
</rss>
